Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the reformulations of existing drugs for the treatment of chronic pain, including therapies manufactured by Johnson & Johnson, Purdue Pharma, Endo Pharmaceuticals, and Cephalon, will drive major market sales from $15 billion in 2004 to more than $24 billion in 2014.

In addition, the new Pharmacor report entitled Chronic Pain: Key Populations, Market Size, and the Driving Force of Drug Reformulations finds that the antidepressant and antiepileptic drug sectors will also experience significant growth over the next decade as a result of new approvals -- and thus more widespread use -- for chronic pain conditions. Specifically, new drugs like duloxetine (Eli Lilly's Cymbalta), Dov Pharmaceutical's bicifadine, pregabalin (Pfizer's Lyrica), and new formulations of gabapentin (Pfizer's Neurontin, generics) are expected to drive growth in the chronic pain market.

"Nonsteroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase (COX)-2 inhibitors, which accounted for nearly 50% of the chronic pain market in 2004, will steadily lose market share in the wake of serious long-term safety issues," said Michelle Grady, therapeutic area director, Pain, at Decision Resources, Inc. "Filling the void left by the declining use of NSAIDs and COX- 2 inhibitors, opioid analgesics and antiepileptic drugs will capture leading shares, together accounting for 55% of the chronic pain therapy market in 2014, compared with a projected 18% NSAID/COX-2 market share that year."

About Chronic Pain

Key chronic pain populations include arthritic pain (primarily osteoarthritis and rheumatoid arthritis pain), chronic low back pain, cancer pain, prominent neuropathic pain conditions (i.e., painful diabetic neuropathy, postherpetic neuralgia, and HIV-related neuropathic pain), fibromyalgia, and chronic headache.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:     Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

Launch of New Drugs From Amgen, Ligand Pharmaceuticals/GlaxoSmithKline to Treat Side Effects of Chemotherapy Will Net Combined Sales of Up to $1.5 Billion

View Now